Diatheva

Diatheva is a private, revenue-generating diagnostics company with a focus on molecular tools for infectious diseases and genetics. Leveraging its expertise in antibody and assay development, the company has established a portfolio of CE-marked kits and reagents for markets including virology, bacteriology, and transfusion medicine. Its business model centers on the sale of diagnostic products and reagents to laboratories, positioning it within the growing global molecular diagnostics market. While detailed financials and pipeline are not publicly disclosed, its long-standing operation since 2001 suggests a stable commercial presence.

Development of molecular diagnostic assays and reagents based on immunoassay (e.g., ELISA, chemiluminescence) and nucleic acid amplification (e.g., PCR) technologies, with core expertise in high-specificity antibody generation.

Diatheva competes in a crowded market dominated by global giants like Roche, Abbott, and bioMérieux, which have broader portfolios and greater resources. Its competitive advantage lies in niche specialization, agility, and deep expertise in specific assay types for targeted laboratory customers.